Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes.
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Curva teorica di concentrazione con un'emivita di 144 h. Modello puramente farmacocinetico — non una raccomandazione di dose.
Open in PK tool →I peptidi arrivano come polvere secca. Una volta disciolti in un liquido (ricostituzione), questo calcolatore risponde a una sola domanda: quanta sostanza c'è in un millilitro di soluzione dopo?
Solo scienza, nessuna vendita. Disiscriviti quando vuoi.
We store your email only for the newsletter. Unsubscribe anytime. Privacy